| Roche Pharma (Schweiz) AG - MabThera subkutan 1600 mg/13.4 ml, Lösung zur subkutanen Injektion |
| 65813 | | 02 | | MabThera subkutan 1600 mg/13.4 ml | | Lösung zur subkutanen Injektion | | L01FA01 | | | | 08.05.2018 | | |
|
| Composition |
| rituximabum 1600 mg, hyaluronidasum humanum ADNr, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 13.4 ml. |
| Packungsbestandteile |
| Lösung zur subkutanen Injektion | | | | | | | | Principe actif | Concentr. |
|---|
| Rituximab | 1600mg / 13.4ml |
| | BAG: Principe actif | Concentr. |
|---|
| Rituximab | 1600 mg |
| | | | Agents auxilliaires |
|---|
| Histidin Hydrochloride Monohydrate | | Histidine | | Hyaluronidasum Humanum Adnr | | Methionine | | Polysorbatum 80 | | Trehalosum Dihydricum |
| |
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | | 2023.78 | 2217.40 | A | LS | Non |
|
